皇冠博彩app
热门标签

Telegram私人频道(www.tel8.vip):Sanofi ends cancer drug trials

时间:1个月前   阅读:1

Telegram私人频道www.tel8.vip)是一个Telegram群组分享平台。Telegram私人频道导出包括Telegram私人频道、telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组(其他)、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。Telegram私人频道为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

新闻电报群www.tel8.vip)是一个Telegram群组分享平台。新闻电报群包括新闻电报群、Telegram群组索引、Telegram群组导航、新加坡Telegram群组、Telegram中文群组、Telegram群组(其他)、Telegram 美国 群组、Telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容。新闻电报群为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。

上一篇:Train service to start at 4.30am on Merdeka Day

下一篇:ERC换TRC:Smaller net loss for Pos Malaysia in 2Q

网友评论